Endpoints News

Endpoints News

Biotech’s groove is back for 2026		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

2 January, 2026

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium meeting space just steps from the action. Reserve your in-person or virtual pass today.

spotlight

In Focus

Gene editing's search for a 'holy grail' has led to an explosion of tools, but few cures

news

Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates

AbbVie taps China again for T cell deal for Zelgen's DLL3-targeted drug

AI biotech Insilico caps the year with a soaring Hong Kong IPO

FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome

Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective date

Ultragenyx, Mereo crash on late-stage bone disease failure

Vanda wins FDA approval for motion sickness drug

Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker

Genmab ends development of Phase 3 lung cancer asset that BioNTech ditched earlier

Nido Bio to wind down after underwhelming Phase 2 data

News Briefing

Chinese siRNA biotech expects $188M IPO; InflaRx seeks Gohibic revival in rare skin condition

Jan 28

11:00am ET

How breakthrough RWE is powering a new era of blood cancer research

sponsored by Flatiron

Jan 22

12:00pm ET

Scaling for a New Era: The Rise of Radiopharma

sponsored by PharmaLogic

in case you missed it

1.

CMS unveils Medicare coverage model for weight loss drugs

2.

J&J axes eczema drug from $1.25B acquisition

3.

Biohaven’s ion channel drug fails again, this time in major depressive disorder

4.

Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B, gets CRL for MS drug

5.

Agios finally gets its thalassemia approval

6.

Drugmakers raise US prices on 350 medicines despite pressure from Trump

Elizabeth Cairns

.

Happy New Year! We’re back and we’ve put together all the headlines you might have missed in the past week and a half!

.

Elizabeth Cairns